Research Groups » de Haan Group » Publications

Publications

2012

Barkhof E, Meijer CJ, de Sonneville LMJ, Linszen DH, de Haan L,Interventions to improve adherence to antipsychotic medication in patients with schizophrenia--a review of the past decade. EUR PSYCHIAT 2012;27 (1):9-18[ PubMed ]
Boonstra N, Sterk B, Wunderink L, Sytema S, de Haan L, Wiersma D,Association of treatment delay, migration and urbanicity in psychosis. EUR PSYCHIAT 2012;ahead of print[ PubMed ]
de Haan L, Sterk B, Wouters L, Linszen DH,The 5-Year Course of Obsessive-Compulsive Symptoms and Obsessive-Compulsive Disorder in First-Episode Schizophrenia and Related Disorders. SCHIZOPHRENIA BULL 2012;ahead of print[ PubMed ]
Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RKR, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Ruhrmann S, Klosterkötter J, Linszen DH [Contributors: McGorry PD, McGlashan TH, Knapp M, van de Fliert R, Klaassen R, Picker H, Neumann M, Brockhaus-Dumke A, Pukrop R, Svirskis T, Huttunen J, Laine T, Ilonen T, Ristkari T, Hietala J, Skeate A, Gudlowski Y, Ozgürdal S, Witthaus H, Lewis S, Morrisson A]] ,Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. ACTA PSYCHIAT SCAND 2012;125 (1):45-53[ PubMed ]
Korver N, Quee PJ, Boos HBM, Simons CJP, de Haan L,Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. INT J METH PSYCH RES 2012;ahead of print[ PubMed ]
Machielsen M, Scheltema Beduin A, Dekker N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I,Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J PSYCHOPHARMACOL 2012;26 (1):189-195[ PubMed ]
Meesters PD, Comijs HC, Dröes RM, de Haan L, Smit JH, Eikelenboom P, Beekman ATF, Stek ML,The Care Needs of Elderly Patients With Schizophrenia Spectrum Disorders. AM J GERIAT PSYCHIAT 2012;ahead of print[ PubMed ]
Meesters PD, de Haan L, Comijs HC, Stek ML, Smeets-Janssen MMJ, Weeda MR, Eikelenboom P, Smit JH, Beekman ATF,Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a dutch catchment area. AM J GERIAT PSYCHIAT 2012;20 (1):18-28[ PubMed ]
Meesters PD, Schouws S, Stek M, de Haan L, Smit J, Eikelenboom P, Beekman A, Comijs H,Cognitive impairment in late life schizophrenia and bipolar I disorder. INT J GERIATR PSYCH 2012;ahead of print[ PubMed ]
Meijer J, Simons CJP, Quee PJ, Verweij K [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] ,Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents. ACTA PSYCHIAT SCAND 2012;125 (1):66-76[ PubMed ]
Rietschel M, Mattheisen M, Degenhardt F, Kahn RS, Linszen DH, Os Jv, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Mühleisen TW, Kirsch P, Esslinger C, Herms S, Demontis D, Steffens M, Strohmaier J, Haenisch B, Breuer R, Czerski PM, Giegling I, Strengman E, Schmael C, Mors O, Mortensen PB, Hougaard DM, Orntoft T, Kapelski P, Priebe L, Basmanav FB, Forstner AJ, Hoffmann P, Meier S, Nikitopoulos J, Moebus S, Alexander M, Mössner R, Wichmann HE, Schreiber S, Rivandeneira F, Hofman A, Uitterlinden AG, Wienker TF, Schumacher J, Hauser J, Maier W, Cantor RM, Erk S, Schulze TG, Stefansson H, Steinberg S, Gustafsson O, Sigurdsson E, Petursson H, Kong A, Stefansson K, Pietiläinen OPH, Tuulio-Henriksson A, Paunio T, Lonnqvist J, Suvisaari J, Peltonen L, Ruggeri M, Tosato S, Walshe M, Murray R, Collier DA, Clair DS, Hansen T, Ingason A, Jakobsen KD, Duong L, Werge T, Melle I, Andreassen OA, Djurovic S, Bitter I, Réthelyi JM, Abramova L, Kaleda V, Golimbet V, Jönsson EG, Terenius L, Agartz I, Winkel Rv, Kenis G, Hert MD, Veldink J, Wiuf C, Didriksen M, Craddock N, Owen MJ, O'Donovan MC, Børglum AD, Rujescu D, Walter H, Meyer-Lindenberg A, Nöthen MM, Ophoff RA, Cichon S,Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. MOL PSYCHIATR 2012;ahead of print[ PubMed ]
Smeerdijk M, Keet R, Dekker N, van Raaij B, Krikke M, Koeter M, de Haan L, Barrowclough C, Schippers G, Linszen D,Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent-onset schizophrenia: a randomized controlled trial. PSYCHOL MED 2012;ahead of print[ PubMed ]
van Beveren NJM, Buitendijk GHS, Swagemakers S, Krab LC, Röder C, de Haan L, van der Spek P, Elgersma Y,Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients. PLOS ONE 2012;7 (2):e32618[ PubMed ]
van Dam DS, van der Ven E, Velthorst E, Selten JP, Morgan C, de Haan L,Childhood bullying and the association with psychosis in non-clinical and clinical samples: a review and meta-analysis. PSYCHOL MED 2012;ahead of print[ PubMed ]
van der Valk R, van de Waerdt S, Meijer CJ, van den Hout I, de Haan L,Feasibility of mindfulness-based therapy in patients recovering from a first psychotic episode: a pilot study. EARLY INTERV PSYCHIATRY 2012;ahead of print[ PubMed ]
Velthorst E, Nieman DH, Veling W, Klaassen RM, Dragt S, Rietdijk J, Ising H, Wunderink L, Linszen DH, de Haan L, van der Gaag M,Ethnicity and baseline symptomatology in patients with an At Risk Mental State for psychosis. PSYCHOL MED 2012;42 (2):247-256[ PubMed ]

2011

Bloemen OJN, Gleich T, de Koning MB, da Silva Alvis F, de Haan L, Linszen DH, Booij J, van Amelsvoort TAMJ,Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. BIOL PSYCHIAT 2011;70 (1):e1-2; author reply e3[ PubMed ]
Boyette L, Swets M, Meijer C, Wouters L [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Factor structure of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) in a large sample of patients with schizophrenia or related disorders and comorbid obsessive-compulsive symptoms. PSYCHIAT RES 2011;186 (2-3):409-413[ PubMed ]
Buizer-Voskamp JE, Muntjewerff JW, Strengman E, Sabatti C, Stefansson H, Vorstman JAS, Ophoff RA [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients. BIOL PSYCHIAT 2011;70 (7):655-662[ PubMed ]
Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, Guo A, van den Oord E, Sullivan PF, Shi J, Levinson DF, Gejman PV, Sanders A, Duan J, Owen MJ, Craddock NJ, O'Donovan MC, Blackman J, Lewis D, Kirov GK, Qin W, Schwab S, Wildenauer D, Chowdari K, Nimgaonkar V, Straub RE, Weinberger DR, O'Neill FA, Walsh D, Bronstein M, Darvasi A, Lencz T, Malhotra AK, Rujescu D, Giegling I, Werge T, Hansen T, Ingason A, Nöethen MM, Rietschel M, Cichon S, Djurovic S, Andreassen OA, Cantor RM, Ophoff R, Corvin A, Morris DW, Gill M, Pato CN, Pato MT, Macedo A, Gurling HMD, McQuillin A, Pimm J, Hultman C, Lichtenstein P, Sklar P, Purcell SM, Scolnick E, St Clair D, Blackwood DHR, Kendler KS [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, O'Donovan MC, Kirov GK, Craddock NJ, Holmans PA, Williams NM, Georgieva L, Nikolov I, Norton N, Williams H, Toncheva D, Milanova V, Owen MJ, Hultman CM, Lichtenstein P, Thelander EF, Sullivan P, Morris DW, O'Dushlaine CT, Kenny E, Quinn EM, Gill M, Corvin A, McQuillin A, Choudhury K, Datta S, Pimm J, Thirumalai S, Puri V, Krasucki R, Lawrence J, Quested D, Bass N, Gurling H, Crombie C, Fraser G, Kuan SL, Walker N, St Clair D, Blackwood DHR, Muir WJ, McGhee KA, Pickard B, Malloy P, Maclean AW, van Beck M, Wray NR, Macgregor S, Visscher PM, Pato MT, Medeiros H, Middleton F, Carvalho C, Morley C, Fanous A, Conti D, Knowles JA, Ferreira CP, Macedo A, Azevedo MH, Pato CN, Stone JL, Ruderfer DM, Kirby AN, Ferreira MAR, Daly MJ, Purcell SM, Sklar P, Chambert K, Kuruvilla F, Gabriel SB, Ardlie K, Moran JL, Scolnick EM]] ,GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. MOL PSYCHIATR 2011;16 (11):1117-1129[ PubMed ]
Collip D, Nicolson NA, Lardinois M, Lataster T, van Os J, Myin-Germeys I [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. PSYCHOL MED 2011;41 (11):2305-2315[ PubMed ]
da Silva Alves F, Boot E, Schmitz N, Nederveen A, Vorstman J, Lavini C, Pouwels PJ, Pouwels P, de Haan L, Linszen D, van Amelsvoort T,Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PLOS ONE 2011;6 (6):e21685[ PubMed ]
da Silva Alves F, Schmitz N, Bloemen O, van der Meer J, Meijer J, Boot E, Nederveen A, de Haan L, Linszen D, van Amelsvoort T,White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. SCHIZOPHR RES 2011;132 (1):75-83[ PubMed ]
da Silva Alves F, Schmitz N, Figee M, Abeling N, Hasler G, van der Meer J, Nederveen A, de Haan L, Linszen D, van Amelsvoort T,Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study. J PSYCHOPHARMACOL 2011;25 (4):538-549[ PubMed ]
Dekker N. Cannabis use in patients with schizophrenia. Motivation for use and relation to clinical variables. s.l.: s.n.; 2011. 206p. ISBN 9789491211843[ UvA Dissertations Online ]Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L, Linszen DH; copromotor(s): Koeter MWJ)
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L,A call for more care when investigating the cannabis-psychosis link Reply. PSYCHIAT RES-NEUROIM 2011;191 (1):85
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L,Reply to fan and hart. PSYCHIAT RES 2011;191 (1):85[ PubMed ]
Dragt S, Nieman DH, Veltman D, Becker HE, van de Fliert R, de Haan L, Linszen DH,Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. SCHIZOPHR RES 2011;125 (1):69-76[ PubMed ]
Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggerman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. BIOL PSYCHIAT 2011;69 (5):487-494[ PubMed ]
Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, Möller HJ, McQuillin A, Muglia P, Cichon S, Rietschel M, Ophoff RA, Djurovic S, Andreassen OA, Pietiläinen OPH, Peltonen L, Dempster E, Collier DA, St Clair D, Rasmussen HB, Glenthøj BY, Kiemeney LA, Franke B, Tosato S, Bonetto C, Saemundsen E, Hreidarsson SJ, Nöthen MM, Gurling H, O'Donovan MC, Owen MJ, Sigurdsson E, Petursson H, Stefansson H, Rujescu D, Stefansson K, Werge T, Linszen D [Contributors: Linszen D, de Haan L, et al -]] ,Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. AM J PSYCHIAT 2011;168 (4):408-417[ PubMed ]
Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietiläinen OPH, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, Gylfason A, Gustafsson O, Olason PI, Steinberg S, Hansen T, Jakobsen KD, Rasmussen HB, Giegling I, Möller HJ, Hartmann A, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Bramon E, Kiemeney LA, Franke B, Murray R, Vassos E, Toulopoulou T, Mühleisen TW, Tosato S, Ruggeri M, Djurovic S, Andreassen OA, Zhang Z, Werge T, Ophoff RA, Rietschel M, Nöthen MM, Petursson H, Stefansson H, Peltonen L, Collier D, Stefansson K, St Clair DM [Contributors: Kahn RS, Cahn W, Linszen D, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] ,Copy number variations of chromosome 16p13.1 region associated with schizophrenia. MOL PSYCHIATR 2011;16 (1):17-25[ PubMed ]
Klaassen RMC, Velthorst E, Nieman DH, de Haan L, Becker HE, Dingemans PM, van de Fliert JR, van der Gaag M, Linszen DH,Factor Analysis of the Scale of Prodromal Symptoms: Differentiating between Negative and Depression Symptoms. PSYCHOPATHOLOGY 2011;44 (6):379-385[ PubMed ]
Korver-Nieberg N, Quee PJ, Boos HB, Simons CJ [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R, van den Berg SE, Schroeder CLA, van der Valk R, Dekker N, Meijer CJ, Korver N, Boyette LN, Meijer J, van Dam D, de Rijke I, Huinink S, de Vries RJ, Jansen M, Bos D, Hoen WP, te West EM, Groeneveld SHJ, Vergunst EM, Swets M, Vothknecht S, Poleacov I, van Dijk D, de Metz S, Hasty MT, Geertsa G, de Baaij PM, Metzger A, van Beveren NJM, Baldini M, Grimbergen FD, Boerma MAM, Agsteribbe C, Wisman HP, Monden MAH, Bosman MM, van Dijk M, Klaassen R, van der Tang T, Luteijn B, Winkel H, Weisz H, Strater ACP, Landman A, Vorstenbosch M, Op 't Eijnde D, Lenders K, Loyen S, Roberts R, Sweers K, Gielen H, Soons N, Hintzen A, Habets V, Risk é I, Vossen C, Martens E, Apers S, Wijnhoven L, Konings E, Lataster T, Lardinois M, Versmissen D, Simons C, van der Werf M, Habets P, Pfeifer S, de Loore E, Heins M, Oorschot M, Meys M, Dietvorst M, van Zelst C, Crolla I, Mengelers R, van Goethem F, Beuken W, Byniam D, Driesen T, Marcelis M, Driessen G, Shazad A, van Winkel R, Henquet C, Kenis G, Delespaul P, Anema P, van Baaren EMJ, Bakker SC, Boos HBM, Caspers E, Derks EM, van Hemert S, Hemkes A, Hijman R, van Leeuwen M, Machielsen JEH, Ophoff RA, Rais M, Salden M, van Someren H, Strengman E, Vleesschouwer M, van Beek M, van Harten PN, Koning JPF, Schep W, Vollema MG, Prins P, Viester T, Akdeniz A, Verweij K, Kaymaz N, v d Heuvel F, v d Goot B, Hovens JE, Loonen AJM, Bous J, Veenstra M, van 't Hag E, Quee PJ, Nienhuis FJ, Smid HGOM, Veermans E, Bartels AA, Duijndam F, Lugtenberg T, Knegtering H, Blaauw W, Wunderink A, Touw KP, Arends J, Slooff CJ, Brilman J, Schomaker M, van Wijk M, Wessels A, Vroom E, Meijerink K, Bogert I, Janssen W, de Berk H, Noorthoorn EO, Ising H, Blom JD, van der Gaag M, Mensen G, van der Snoek R, Smit R, Faber G]] ,The validity of the DSM-IV diagnostic classification system of non-affective psychoses. AUST NZ J PSYCHIAT 2011;45 (12):1061-1068[ PubMed ]
Lataster J, van Os J, de Haan L, Thewissen V, Bak M, Lataster T, Lardinois M, Delespaul PAGE, Myin-Germeys I,Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. J CLIN PSYCHIAT 2011;72 (10):1397-1404[ PubMed ]
Meesters PD, Comijs HC, de Haan L, Smit JH, Eikelenboom P, Beekman ATF, Stek ML,Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia. SCHIZOPHR RES 2011;126 (1-3):237-244[ PubMed ]
Meijer JH, Schmitz N, Nieman DH, Becker HE, van Amelsvoort TAMJ, Dingemans PM, Linszen DH, de Haan L,Semantic fluency deficits and reduced grey matter before transition to psychosis: a voxelwise correlational analysis. PSYCHIAT RES 2011;194 (1):1-6[ PubMed ]
Muntjewerff JW, Ophoff RA, Buizer-Voskamp JE, Strengman E, den Heijer M [Contributors: Linszen DH, de Haan L, et al -]] ,Effects of season of birth and a common MTHFR gene variant on the risk of schizophrenia. EUR NEUROPSYCHOPHARM 2011;21 (4):300-305[ PubMed ]
Quee PJ, van der Meer L, Bruggeman R, de Haan L, Krabbendam L, Cahn W, Mulder NCL, Wiersma D, Aleman A,Insight in Psychosis: Relationship With Neurocognition, Social Cognition and Clinical Symptoms Depends on Phase of Illness. SCHIZOPHRENIA BULL 2011;37 (1):29-37[ PubMed ]
Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DHR, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, de Hert M, Jönsson EG, Bitter I, Pietiläinen OPH, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Orntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CCA, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV,Genome-wide association study identifies five new schizophrenia loci. NAT GENET 2011;43 (10):969-976[ PubMed ]
Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L,Ultra high-risk state for psychosis and non-transition: a systematic review. SCHIZOPHR RES 2011;132 (1):8-17[ PubMed ]
Steinberg S, de Jong S, Andreassen OA, Werge T, Børglum AD, Mors O, Mortensen PB, Gustafsson O, Costas J, Pietiläinen OPH, Demontis D, Papiol S, Huttenlocher J, Mattheisen M, Breuer R, Vassos E, Giegling I, Fraser G, Walker N, Tuulio-Henriksson A, Suvisaari J, Lönnqvist J, Paunio T, Agartz I, Melle I, Djurovic S, Strengman E, Jürgens G, Glenthøj B, Terenius L, Hougaard DM, Ørntoft T, Wiuf C, Didriksen M, Hollegaard MV, Nordentoft M, van Winkel R, Kenis G, Abramova L, Kaleda V, Arrojo M, Sanjuán J, Arango C, Sperling S, Rossner M, Ribolsi M, Magni V, Siracusano A, Christiansen C, Kiemeney LA, Veldink J, van den Berg L, Ingason A, Muglia P, Murray R, Nöthen MM, Sigurdsson E, Petursson H, Thorsteinsdottir U, Kong A, Rubino IA, de Hert M, Réthelyi JM, Bitter I, Jönsson EG, Golimbet V, Carracedo A, Ehrenreich H, Craddock N, Owen MJ, O'Donovan MC, Ruggeri M, Tosato S, Peltonen L, Ophoff RA, Collier DA, St Clair D, Rietschel M, Cichon S, Stefansson H, Rujescu D, Stefansson K [Contributors: Linszen DH, de Haan L, et al -]] ,Common variants at VRK2 and TCF4 conferring risk of schizophrenia. HUM MOL GENET 2011;20 (20):4076-4081[ PubMed ]
Steinberg S, Mors O, Børglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Böttcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietiläinen OPH, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonnqvist J, Paunio T, Hartmann A, Jürgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Möller HJ, Giegling I, Glenthøj B, Rasmussen HB, Mattheisen M, Bitter I, Réthelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St Clair D, Stefansson K [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] ,Expanding the range of ZNF804A variants conferring risk of psychosis. MOL PSYCHIATR 2011;16 (1):59-66[ PubMed ]
Sterk B, Lankreijer K, Linszen DH, de Haan L,Obsessive-compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis; onset and relationship to psychotic symptoms. AUST NZ J PSYCHIAT 2011;45 (5):400-406[ PubMed ]
van Tricht MJ, Nieman DH, Koelman JHTM, Bour LJ, van der Meer JN, van Amelsvoort TA, Linszen DH, de Haan L,Auditory ERP components before and after transition to a first psychotic episode. BIOL PSYCHOL 2011;87 (3):350-357[ PubMed ]
van Winkel R [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-up. ARCH GEN PSYCHIAT 2011;68 (2):148-157[ PubMed ]
van Winkel R, van Beveren NJM, Simons C, S Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I,AKT1 Moderation of Cannabis-Induced Cognitive Alterations in Psychotic Disorder. NEUROPSYCHOPHARMACOL 2011;36 (12):2529-2537[ PubMed ]
Velthorst E. The lonely soul wanders. On the role of impaired social functioning in the prediction of first psychosis. s.l.: s.n.; 2011. 191p. ISBN 9789090263083[ UvA Dissertations Online ]Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, de Haan L; copromotor(s): Nieman DH)
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, de Haan L,Three-year course of clinical symptomatology in young people at ultra high risk for transition to psychosis. ACTA PSYCHIAT SCAND 2011;123 (1):36-42[ PubMed ]
Velthorst E, Nieman DH, Meijer C, Linszen D, de Haan L,Social Disability at Admission for a First Psychosis Does Not Predict Clinical Outcome at 5-Year Follow-Up. J NERV MENT DIS 2011;199 (7):510-512[ PubMed ]
Vothknecht S, Schoevers RA, de Haan L,Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. AUST NZ J PSYCHIAT 2011;45 (3):182-192[ PubMed ]
[Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Evidence That Familial Liability for Psychosis Is Expressed as Differential Sensitivity to Cannabis An Analysis of Patient-Sibling and Sibling-Control Pairs. ARCH GEN PSYCHIAT 2011;68 (2):138-147[ PubMed ]

2010

Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, de Haan L, Linszen DH,Verbal fluency as a possible predictor for psychosis. EUR PSYCHIAT 2010;25 (2):105-110[ PubMed ]
Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, de Haan L, van Amelsvoort TA, Linszen DH,Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration?. PSYCHOL MED 2010;40 (10):1599-1606[ PubMed ]
Bloemen OJN, de Koning MB, Schmitz N, Nieman DH, Becker HE, de Haan L, Dingemans P, Linszen DH, van Amelsvoort TAMJ,White-matter markers for psychosis in a prospective ultra-high-risk cohort. PSYCHOL MED 2010;40 (8):1297-1304[ PubMed ]
Boerma MAM, van der Stel JC, van Amelsvoort T, Linszen DH, de Haan L,Vrouwen, schizofrenie en oestrogeen; neurobiologische hypothesen en interventiestudies. TIJDSCHR PSYCHIATR 2010;52 (4):235-244[ PubMed ]
Boot E, Booij J, Zinkstok JR, de Haan L, Linszen DH, Baas F, van Amelsvoort TA,Striatal D₂ receptor binding in 22q11 deletion syndrome: an [¹²³I]IBZM SPECT study. J PSYCHOPHARMACOL 2010;24 (10):1525-1531[ PubMed ]
de Haan L,Onderzoek de toekomst. TIJDSCHR PSYCHIATR 2010;52 (9):611-613[ PubMed ]
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L,Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. PSYCHIAT RES-NEUROIM 2010;181 (1):51-56[ PubMed ]
Dekker N, Smeerdijk AM, Wiers RW, Duits JH, van Gelder G, Houben K, Schippers G, Linszen DH, de Haan L,Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls. PSYCHOL MED 2010;40 (8):1325-1336[ PubMed ]
Dragt S, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, de Haan L, van Amelsvoort TA, Linszen DH,Age of Onset of Cannabis Use Is Associated With Age of Onset of High-Risk Symptoms for Psychosis. CAN J PSYCHIAT 2010;55 (3):165-171[ PubMed ]
Ingason A, Giegling I, Cichon S, Hansen T, Rasmussen HB, Nielsen J, Jürgens G, Muglia P, Hartmann AM, Strengman E, Vasilescu C, Mühleisen TW, Djurovic S, Melle I, Lerer B, Möller HJ, Francks C, Pietiläinen OPH, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Walshe M, Vassos E, Di Forti M, Murray R, Bonetto C, Tosato S, Cantor RM, Rietschel M, Craddock N, Owen MJ, Peltonen L, Andreassen OA, Nöthen MM, St Clair D, Ophoff RA, O'Donovan MC, Collier DA, Werge T, Rujescu D [Contributors: Kahn RS, Cahn W, Linszen D, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] ,A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. HUM MOL GENET 2010;19 (7):1379-1386[ PubMed ]
Karagianis J, Landry J, Hoffmann VP, Grossman L, de Haan L, Maguire G, Milev R, Holt S,An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study. INT J CLIN PRACT 2010;64 (11):1520-1529[ PubMed ]
Korver N, Nieman DH, Becker HE, van de Fliert JR, Dingemans PH, de Haan L, Spiering M, Schmitz N, Linszen DH,Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. AUST NZ J PSYCHIAT 2010;44 (3):230-236[ PubMed ]
Machielsen M, van der Sluis S, de Haan L,Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic and pre-psychotic symptoms. AUST NZ J PSYCHIAT 2010;44 (8):721-728[ PubMed ]
Meesters PD, Stek ML, Comijs HC, de Haan L, Patterson TL, Eikelenboom P, Beekman ATF,Social Functioning Among Older Community-Dwelling Patients With Schizophrenia: A Review. AM J GERIAT PSYCHIAT 2010;18 (10):862-878[ PubMed ]
Mulder CL, van der Gaag M, Bruggeman R, Cahn W, Delespaul PAE, Dries P, Faber G, de Haan L, van der Heijden FMMA, Kempen RW, Mogendorff ESG, Slooff CJ, Sytema S, Wiersma D, Wunderink L, van Os J,Routine outcome monitoring voor patiënten met ernstige psychiatrische aandoeningen; een consensusdocument. TIJDSCHR PSYCHIATR 2010;52 (3):169-179[ PubMed ]
Peters BD. White matters. Diffusion tensor imaging in the early ohase of schizophrenia. s.l.: s.n.; 2010. 185p.[ UvA Dissertations Online ]Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, den Heeten GJ; copromotor(s): de Haan L, Majoie CB)
Peters BD, Blaas J, de Haan L,Diffusion tensor imaging in the early phase of schizophrenia What have we learned?. J PSYCHIATR RES 2010;44 (15):993-1004[ PubMed ]
Peters BD, Dingemans PM, Dekker N, Blaas J, Akkerman E, van Amelsvoort TA, Majoie CB, den Heeten GJ, Linszen DH, de Haan L,White matter connectivity and psychosis in ultra-high-risk subjects: A diffusion tensor fiber tracking study. PSYCHIAT RES-NEUROIM 2010;181 (1):44-50[ PubMed ]
Scheltema Beduin A, de Haan L,Off-label second generation antipsychotics for impulse regulation disorders: a review. PSYCHOPHARMACOL BULL 2010;43 (3):45-81[ PubMed ]
Sterk B, Slief EM, Blankers M, Linszen DH, de Haan L,Duration of untreated psychosis and ethnicity. SCHIZOPHR RES 2010;124 (1-3):238-239[ PubMed ]
Talamini LM, de Haan L, Nieman DH, Linszen DH, Meeter M,Reduced Context Effects on Retrieval in First-Episode Schizophrenia. PLOS ONE 2010;5 (4):e10356[ PubMed ]
Tricht MJv, Nieman DH, Koelman JHTM, van der Meer JN, Bour LJ, de Haan L, Linszen DH,Reduced Parietal P300 Amplitude is Associated with an Increased Risk for a First Psychotic Episode. BIOL PSYCHIAT 2010;68 (7):642-648[ PubMed ]
van der Post LFM, Dekker JJM, Jonkers JFJ, Beekman ATF, Mulder CL, de Haan L, Mulder WG, Schoevers RA,Crisis intervention and acute psychiatry in Amsterdam, 20 years of change: a historical comparison of consultations in 1983 and 2004-2005. INT J SOC PSYCHIATR 2010;56 (4):348-358[ PubMed ]
van Nimwegen-Campailla L, van Beveren N, Laan W, van den Brink W, Linszen D, de Haan L,Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis. PHARMACOPSYCHIATRY 2010;43 (7):281-282[ PubMed ]
Van Tricht MJ, Nieman DH, Bour LJ, Boerée T, Koelman JHTM, de Haan L, Linszen DH,Increased saccadic rate during smooth pursuit eye movements in patients at Ultra High Risk for developing a psychosis. BRAIN COGNITION 2010;73 (3):215-221[ PubMed ]
Velthorst E, Nieman DH, Linszen D, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RKR, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, French P, Stevens H, Schultze-Lutter F, Klosterkötter J, Ruhrmann S,Disability in people clinically at high risk of psychosis. BRIT J PSYCHIAT 2010;197 (4):278-284[ PubMed ]

2009

de Haan L,Bewegen. TIJDSCHR PSYCHIATR 2009;51 (5):275-277[ PubMed ]
de Haan L, Dudek-Hodge C, Verhoeven Y, Denys D,Prevalence of psychotic disorders in patients with obsessive-compulsive disorder. CNS SPECTRUMS 2009;14 (8):415-417[ PubMed ]
Dekker N, Linszen DH, de Haan L,Reasons for Cannabis Use and Effects of Cannabis Use as Reported by Patients with Psychotic Disorders. PSYCHOPATHOLOGY 2009;42 (6):350-360[ PubMed ]
Karagianis J, Grossman L, Landry J, Reed VA, de Haan L, Maguire GA, Hoffmann VP, Milev R,A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. SCHIZOPHR RES 2009;113 (1):41-48[ PubMed ]
Machielsen MWJ, de Haan L,Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. PSYCHOPHARMACOL BULL 2009;42 (4):40-52[ PubMed ]
Nieman DH, Rike WH, Becker HE, Dingemans PM, van Amelsvoort TA, Haan Ld, der Gaag Mv, Denys DAJP, Linszen DH,Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. INT CLIN PSYCHOPHARM 2009;24 (4):223-228[ PubMed ]
Peters BD, de Haan L, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH,Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity?. PSYCHOPHARMACOL BULL 2009;42 (2):75-88[ PubMed ]
Peters BD, de Koning P, Dingemans P, Becker H, Linszen DH, de Haan L,Subjective effects of cannabis before the first psychotic episode. AUST NZ J PSYCHIAT 2009;43 (12):1155-1162[ PubMed ]
Peters BD, Duran M, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, de Haan L,Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study. PROSTAG LEUKOTR ESS 2009;81 (1):61-63[ PubMed ]
Peters B, de Haan L,Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. PROG NEURO-PSYCHOPH 2009;33 (8):1576-1577[ PubMed ]
Peters BD, Schmitz N, Dingemans PM, van Amelsvoort TA, Linszen DH, de Haan L, Majoie CB, den Heeten GJ,Preliminary evidence for reduced frontal white matter integrity in subjects at ultra-high-risk for psychosis. SCHIZOPHR RES 2009;111 (1-3):192-193[ PubMed ]
Rujescu D, Ingason A, Cichon S, Pietiläinen OPH, Barnes MR, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann AM, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Djurovic S, Melle I, Andreassen OA, Hansen T, Werge T, Kiemeney LA, Franke B, Veltman J, Buizer-Voskamp JE, Sabatti C, Ophoff RA, Rietschel M, Nöthen MM, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier DA [Contributors: Kahn RS, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Disruption of the neurexin 1 gene is associated with schizophrenia. HUM MOL GENET 2009;18 (5):988-996[ PubMed ]
Staring ABP, Mulder CL, Duivenvoorden HJ, de Haan L, van der Gaag M,Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. SCHIZOPHR RES 2009;113 (1):27-33[ PubMed ]
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OPH, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Common variants conferring risk of schizophrenia. NATURE 2009;460 (7256):744-747[ PubMed ]
van Bruggen M, van Amelsvoort T, Wouters L, Dingemans P, de Haan L, Linszen D,Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. PSYCHONEUROENDOCRINO 2009;34 (7):989-995[ PubMed ]
van der Post LFM, Dekker JJM, Jonkers JFJ, Beekman ATF, Mulder CL, de Haan L, Mulder WG, Schoevers RA,Veranderingen in crisisinterventie en acute psychiatrie; Amsterdamse consulten in 1983 en 2005. TIJDSCHR PSYCHIATR 2009;51 (3):139-150[ PubMed ]
Velthorst E, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, Klaassen R, de Haan L, van Amelsvoort T, Linszen DH,Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. SCHIZOPHR RES 2009;109 (1-3):60-65[ PubMed ]

2008

Boot E, Booij J, Hasler G, Zinkstok JR, de Haan L, Linszen DH, van Amelsvoort TA,AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. EUR J NUCL MED MOL I 2008;35 (7):1350-1356[ PubMed ]
Boot E, Booij J, Zinkstok J, Abeling N, de Haan L, Baas F, Linszen D, van Amelsvoort T,Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. NEUROPSYCHOPHARMACOL 2008;33 (6):1252-1258[ PubMed ]
Cahn W, Ramlal D, Bruggeman R, de Haan L, Scheepers FE, van Soest MM, Assies J , Slooff CJ,Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. TIJDSCHR PSYCHIATR 2008;50 (9):579-591[ PubMed ]
da Silva Alves F, Figee M, van Avamelsvoort T, Veltman D, de Haan L,The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. PSYCHOPHARMACOL BULL 2008;41 (1):121-132[ PubMed ]
de Haan L, van Nimwegen L, van Amelsvoort T, Dingemans P, Linszen D,Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. PHARMACOPSYCHIATRY 2008;41 (4):125-128[ PubMed ]
Dekker N, de Haan L, van den Berg S, de Gier M, Becker H, Linzen DH,Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders. PSYCHOPHARMACOL BULL 2008;41 (1):142-153[ PubMed ]
Denys D, de Haan L,25 jaar antipsychotica: back to the future?. TIJDSCHR PSYCHIATR 2008;50 (13):105-109[ PubMed ]
Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Sabatti C, Geurts van Kessel A, Brunner HG, Ophoff RA, Veltman JA,Genetic Risk and Outcome in Psychosis. AM J HUM GENET 2008;83 (4):504
Karagianis J, Hoffmann VP, Arranz B, Treuer T, Maguire GA, de Haan L, Chawla B,Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. HUM PSYCHOPHARM CLIN 2008;23 (4):275-281[ PubMed ]
Maat A, Fouwels A , de Haan L,Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. PSYCHOPHARMACOL BULL 2008;41 (3):5-10[ PubMed ]
Peters BD, de Haan L, Dekker N, Blaas J, Becker HE, Dingemans PM, Akkerman EM, Majoie CB, van Amelsvoort T, den Heeten GJ, Linszen DH,White matter fibertracking in first-episode schizophrenia, schizoaffective patients and subjects at ultra-high risk of psychosis. NEUROPSYCHOBIOLOGY 2008;58 (1):19-28[ PubMed ]
Stefansson H, Rujescu D, Cichon S, Pietiläinen OPH, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Möller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Mühleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nöthen MM, Peltonen L, Collier DA, St Clair D, Stefansson K [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Large recurrent microdeletions associated with schizophrenia. NATURE 2008;455 (7210):232-236[ PubMed ]
van Amelsvoort T, Zinkstok J, Figee M, Daly E, Morris R, Owen MJ, Murphy KC, de Haan L, Linszen DH, Glaser B, Murphy DGM,Effects of a functional COMT polymorphism on brain anatomy and cognitive function in adults with velo-cardio-facial syndrome. PSYCHOL MED 2008;38 (1):89-100[ PubMed ]
van Beveren NJM, de Haan L,A visual metaphor describing neural dynamics in schizophrenia. PLOS ONE 2008;3 (7):e2577[ PubMed ]
van der Post L, Schoevers R, Koppelmans V, Visch I, Bernardt C, Mulder N, Beekman A, de Haan L, Dekker J,The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area. BMC PSYCHIATRY 2008;8 (1):35[ PubMed ]
van Nimwegen L, de Haan L, van Beveren N, Laan W, van den Brink W, Linszen D,Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. J CLIN PSYCHOPHARM 2008;28 (2):214-218[ PubMed ]
van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D,Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. CAN J PSYCHIAT 2008;53 (6):400-405[ PubMed ]
van Nimwegen LJM. Well-being and co-morbidity in recent onset schizophrenia. s.l.: s.n.; 2008. 167p. ISBN 9789085594178[ UvA Dissertations Online ]Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, Hengeveld MW; copromotor(s): de Haan L, van den Brink W)
van Nimwegen LJM, Storosum JG, Blumer RME, Allick G, Venema HW, de Haan L, Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJM, Sauerwein HP,Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J CLIN ENDOCR METAB 2008;93 (2):572-577[ PubMed ]
Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E, Sabatti C, Geurts van Kessel A, Brunner HG, Ophoff RA, Veltman JA [Contributors: Kahn RS, Linszen DH, Os Jv, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] ,Recurrent CNVs disrupt three candidate genes in schizophrenia patients. AM J HUM GENET 2008;83 (4):504-510[ PubMed ]
Zinkstok J, van Nimwegen L, van Amelsvoort T, de Haan L, Yusuf MA, Baas F, Linszen D,Catechol-O-methyltransferase gene and obsessive-compulsive symptoms in patients with recent-onset schizophrenia: Preliminary results. PSYCHIAT RES 2008;157 (1-3):1-8[ PubMed ]
[Contributors: Leboyer M, Meyer-Lindenberg A, Stefanis N, Rutten BPF, Arango C, Jones P, Kapur S, Lewis S, Murray R, Owen MJ, Linszen D, Kahn R, van Os J, Wiersma D, Bruggeman R, Cahn W, Germeys I, de Haan L, Krabbendam L]] ,Schizophrenia aetiology: do gene-environment interactions hold the key?. SCHIZOPHR RES 2008;102 (1-3):21-26[ PubMed ]

2007

de Haan L,Alledaagse vragen en wetenschap. TIJDSCHR PSYCHIATR 2007;49 (11):785-788[ PubMed ]
de Haan L, van Amelsvoort T, Dingemans P, Linszen D,Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. PHARMACOPSYCHIATRY 2007;40 (6):264-268[ PubMed ]
Thijs WJ, Karrenbeld A, van der Zouwen L, de Haan L,Metastatic endometrial cancer; a rare intestinal localization. ENDOSCOPY 2007;39 Suppl 1 (S 1):E131[ PubMed ]
van Nimwegen L, de Haan L, van Beveren N, van den Brink W, Linszen D,Adolescentie, schizofrenie en drugs: interacterende kwetsbaarheid. Een hypothese. TIJDSCHR PSYCHIATR 2007;49 (3):169-178[ PubMed ]

2006

Barkhof E, de Haan L, Meijer CJ, Fouwels AJ , Keet IPM, Hulstijn KP, Schippers GM, Linszen DH,Motivational interviewing in psychotic disorders. CURR PSYCHIAT REV 2006;2:207-213
de Haan L,Ontwikkeling van psychopathologie. TIJDSCHR PSYCHIATR 2006;48 (5):359-360[ PubMed ]
de Haan L, Booij J, Lavalaye J, van Amelsvoort T, Linszen D,Occupancy of dopamine D-2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. PSYCHOPHARMACOLOGY 2006;183 (4):500-505[ PubMed ]
de Haan L, Hoogeboom B, Beuk N, Wouters L, Dingemans PMAJ, Linszen DH,Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. PSYCHOPHARMACOL BULL 2006;39 (1):25-30[ PubMed ]
van Beveren NJM, van der Spelt JJ, de Haan L, Fekkes D,Schizophrenia-associated neural growth factors in peripheral blood. A review. EUR NEUROPSYCHOPHARM 2006;16 (7):469-480[ PubMed ]
van der Gaag M, Cuijpers A, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Wiersma D,The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. SCHIZOPHR RES 2006;85 (1-3):273-279[ PubMed ]
van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Cuijpers A, Wiersma D,The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. SCHIZOPHR RES 2006;85 (1-3):280-287[ PubMed ]
van Nimwegen L, de Haan L,Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis. PSYCHOPATHOLOGY 2006;39 (3):158[ PubMed ]
Weeda MR, Peters BD, de Haan L, Linszen DH,Blijvende neuropsychologische stoornissen en structurele en functionele hersenafwijkingen na langdurig cannabisgebruik. TIJDSCHR PSYCHIATR 2006;48 (3):185-193[ PubMed ]

2005

de Haan L,Het optimale niveau van dopaminerge neurotransmissie. NED TIJDSCHR GENEESKD 2005;149 (31):1721-1722[ PubMed ]
de Haan L, Booij J, Lavalye J, van Amelsvoort T, Linszen D,Subjective experiences during dopamine depletion. AM J PSYCHIAT 2005;162 (9):1755[ PubMed ]
de Haan L, Hoogenboom B, Beuk N, van Amelsvoort T, Linszen D,Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders. CAN J PSYCHIAT 2005;50 (9):519-524[ PubMed ]
de Haan L, Lavalaye J, Booij J, Linszen D,Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics. AM J PSYCHIAT 2005;162 (8):1544-1545[ PubMed ]
de Haan L, van Beveren N,Olanzapine and haloperidol for residual symptoms. AM J PSYCHIAT 2005;162 (7):1392-1393[ PubMed ]
Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJT, de Haan L, van Hout BA,Modelling the treated course of schizophrenia: Development of a discrete event simulation model. PHARMACOECONOMICS 2005;23 (Suppl. 1):17-33[ PubMed ]
van Nimwegen L, de Haan L, van Beveren N, van den Brink W, Linszen D,Adolescence, schizophrenia and drug abuse: a window of vulnerability. ACTA PSYCHIAT SCAND 2005;111 (Suppl. 427):35-42[ PubMed ]
Zinkstok J, van Amelsvoort T, de Haan L, Baas F, Linszen DH. The catechol-O-methyltransferase gene and schizofphreniain: Lang MV, editors. Trends in schizophrenia research. S.l.: Nova Science Publishers, Inc; 2005., p. 45-78

2004

Boot E, de Haan L, Guzelcan Y, Scholte WF, Assies H,Pericardial and bilateral pleural effusion associated with clozapine treatment. EUR PSYCHIAT 2004;19 (1):65[ PubMed ]
de Haan L, Bakker JM,Overview of neuropathological theories of schizophrenia: From degeneration to progressive developmental disorder. PSYCHOPATHOLOGY 2004;37 (1):1-7[ PubMed ]
de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, Linszen D,Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. CAN J PSYCHIAT 2004;49 (5):290-296[ PubMed ]
de Haan L, Oekeneva A, van Amelsvoort T, Linszen D,Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders. EUR PSYCHIAT 2004;19 (8):524[ PubMed ]
de Haan L, van Amelsvoort T, Linszen DH,Elevated homocysteine levels in schizophrenia. AM J PSYCHIAT 2004;161 (6):1131-1132[ PubMed ]
de Haan L, van Amelsvoort T, Rosien K, Linszen D,Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. PSYCHOPHARMACOLOGY 2004;175 (3):389-390[ PubMed ]
de Haan L, van Beveren N,Olanzapine vs haloperidol for treatment of schizophrenia. JAMA-J AM MED ASSOC 2004;291 (9):1065-1065; author reply 1066[ PubMed ]
de Haan L, Welborn K, Krikke M, Linszen DH,Opinions of mothers on the first psychotic episode and the start of treatment of their child. EUR PSYCHIAT 2004;19 (4):226-229[ PubMed ]
Sluys M, Güzelcan Y, Casteelen G, de Haan L,Risperidone-induced leucopenia and neutropenia: a case report. EUR PSYCHIAT 2004;19 (2):117[ PubMed ]

2003

de Haan L, Linszen DH, Lenior ME, de Win ED, Gorsira R,Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. SCHIZOPHRENIA BULL 2003;29 (2):341-348[ PubMed ]
de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PMAJ, Linszen D,Subjective experience and D-2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: A randomized, double-blind study. AM J PSYCHIAT 2003;160 (2):303-309[ PubMed ]
Storosum JG, van Zwieten BJ, Wohlfarth T, de Haan L, Khan A, van den Brink W,Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. ARCH GEN PSYCHIAT 2003;60 (4):365-368[ PubMed ]
van der Gaag M, Wolthaus J, de Haan L, Wykes T,School performance in secundary education shows no decline before the onset of a first episode of psychosis in schizophrenia. J MENT HEALTH 2003;12 (6):585-593

2002

de Haan L. Patients' perspectives. Subjective experiences and attitudes of patients with recent onset schizophrenia. S.l.: s.n.; 2002. 227p. ISBN 90-9015265-2[ UvA Dissertations Online ]Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, Gersons BPR; copromotor(s): Dingemans PMAJ)
de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D,Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: A prospective study of 113 patients with recent-onset schizophrenia or related disorders. J CLIN PSYCHIAT 2002;63 (2):104-107[ PubMed ]
de Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L,Priorities and satisfaction on the help needed and provided in a first episode of psychosis. A survey in five European Family Associations. EUR PSYCHIAT 2002;17 (8):425-433[ PubMed ]
de Haan L, Peters B, Dingemans P, Wouters L, Linszen D,Attitudes of patients toward the first psychotic episode and the start of treatment. SCHIZOPHRENIA BULL 2002;28 (3):431-442[ PubMed ]
de Haan L, van Amelsvoort T,Comparable dopamine 2 receptor occupancy. AM J PSYCHIAT 2002;159 (12):2118-2118; author reply 2119[ PubMed ]
de Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L,Psychometric properties of the Subjective Well-Being Under Neuroleptics Scale and the Subjective Deficit Syndrome Scale. PSYCHOPHARMACOLOGY 2002;162 (1):24-28[ PubMed ]
Denys D, de Haan L,Reply to Neurotic Excoriations and OCD. TIJDSCHR PSYCHIATR 2002;44:409-411
Güzelcan Y, de Haan L, Scholte WF,Risperidone may induce mania. PSYCHOPHARMACOLOGY 2002;162 (1):85-86[ PubMed ]
Güzelcan Y, van Amelsvoort T, de Haan L, van Schaik P, Linszen DH,Schizofrenie en het 22q11-deletiesyndroom. NED TIJDSCHR GENEESKD 2002;146 (43):2019-2021[ PubMed ]
Jonkers F, de Haan L,Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder. PSYCHOPHARMACOLOGY 2002;162 (1):87-88[ PubMed ]
Storosum J, van Zwieten B, de Haan L,Informed consent from behaviourally disturbed patients. LANCET 2002;359 (9300):83[ PubMed ]

2001

de Haan L, van Raaij B, van den Berg R, Jager M, Houweling P, Stockmann M, Delsing P, Linszen D, Peters B, Wouters L,Preferences for treatment during a first psychotic episode. EUR PSYCHIAT 2001;16 (2):83-89[ PubMed ]
Lenior ME, Dingemans PM, Linszen DH, de Haan L, Schene AH,Social functioning and the course of early-onset schizophrenia: five-year follow-up of a psychosocial intervention. BRIT J PSYCHIAT 2001;179:53-58[ PubMed ]

2000

de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J,Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. AM J PSYCHIAT 2000;157 (6):1019-1020[ PubMed ]

1999

de Haan L, Linszen DH, Gorsira R,Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J CLIN PSYCHIAT 1999;60 (6):364-365[ PubMed ]

1998

Linszen DH, Dingemans PM, Lenior ME, Scholte WF , de Haan L, Goldstein MJ,Early detection and intervention in schizophrenia. INT CLIN PSYCHOPHARM 1998;13 (Suppl. 3):S31-S34[ PubMed ]
Linszen D, Lenior M, de Haan L, Dingemans P, Gersons B,Early intervention, untreated psychosis and the course of early schizophrenia. BR J PSYCHIATRY SUPPL 1998;172 (33):84-89[ PubMed ]